Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
- Conditions
- OsteoporosisLiver TransplantationFractures
- First Posted Date
- 2005-06-16
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
- Target Recruit Count
- 100
- Registration Number
- NCT00114556
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
- Conditions
- Breast CancerOsteoporosis
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- University of Virginia
- Registration Number
- NCT00114270
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- Breast CancerOsteoporosis
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 558
- Registration Number
- NCT00107263
A Multiple Myeloma Trial in Patients With Bone Metastases
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 179
- Registration Number
- NCT00104104
- Locations
- 🇺🇸
Osceola Cancer Center, Kissimmee, Florida, United States
🇺🇸Maryland Oncology-Hematology PA, Columbia, Maryland, United States
🇺🇸Fox Valley Hematology Oncology SC, Appleton, Wisconsin, United States
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- Conditions
- Paget's Disease of Bone
- Interventions
- Drug: placebo to zoledronic acid
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00103740
- Locations
- 🇬🇧
Novartis Investigative site, Oxford, United Kingdom
🇬🇧Novartis Investigative Site, London, United Kingdom
Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density
- Conditions
- HIV InfectionsOsteopeniaOsteoporosis
- Interventions
- First Posted Date
- 2005-02-07
- Last Posted Date
- 2008-09-26
- Target Recruit Count
- 30
- Registration Number
- NCT00102908
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
- Conditions
- Osteoporosis
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 802
- Registration Number
- NCT00100620
- Locations
- 🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸United Osteoporosis Centers, Gainesville, Georgia, United States
🇺🇸Center for Education and research on Therapeutics (CERTs) of Musculoskeletal Disorders, Birmingham, Alabama, United States
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
- Conditions
- Osteoporosis
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00100555
- Locations
- 🇺🇸
St. Luke's Episcopal Hospital Ctr for Ortho. Res. and Education, Houston, Texas, United States
🇺🇸Univ. of Alabama/Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, United States
🇺🇸Denver Arthritis Clinic, Denver, Colorado, United States
Non-small Cell Lung Cancer Registry
- Conditions
- Non-Small-Cell Lung CancerPleural Effusion, Malignant
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00099541
- Locations
- 🇺🇸
Hembree Cancer Center-St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸Gainesville Hematology Oncology Associates, Gainesville, Florida, United States
🇺🇸Center for Cancer Care & Research, Lakeland, Florida, United States
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
- Conditions
- Bone NeoplasmNeoplasm MetastasisPain
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00099177
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.